CD274 and Skin rash: In addition, anti-PD-1/PD-L1 antibodies treatment presents less toxicity (most common events being hypothyroidism, hyperthyroidism, skin rash, pneumonitis, and hepatitis) and better overall survival, progression free survival and overall response rate than docetaxel, mainly for higher levels of PD-L1 expression, and even when PD-L1 expression is < 1%[4, 22, 103].